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ABSTRACT
Introduction The Its Not JUST Idiopathic pulmonary fibrosis 
Study (INJUSTIS) is a multicentre, prospective, observational 
cohort study. The aims of this study are to identify genetic, 
serum and other biomarkers that may identify specific 
molecular mechanisms, reflecting disease endotypes that are 
shared among patients with progressive pulmonary fibrosis 
regardless of aetiology. Furthermore, it is anticipated that 
these biomarkers will help predict fibrotic activity that may 
identify patterns of disease behaviour with greater accuracy 
than current clinical phenotyping.
Methods and analysis 200 participants with the 
multidisciplinary team confirmed fibrotic lung disease 
(50 each of rheumatoid-interstitial lung disease (ILD), 
asbestosis, chronic hypersensitivity pneumonitis and 
unclassifiable ILD) and 50 idiopathic pulmonary fibrosis 
participants, recruited as positive controls, will be followed 
up for 2 years. Participants will have blood samples, lung 
function tests, quality of life questionnaires and a subgroup 
will be offered bronchoscopy. Participants will also be 
given the option of undertaking blinded home handheld 
spirometry for the first 3 months of the study. The primary 
end point will be identification of a biomarker that predicts 
disease progression, defined as 10% relative change in 
forced vital capacity (FVC) or death at 12 months.
Ethics and dissemination The trial has received ethical 
approval from the National Research Ethics Committee 
Nottingham (18/EM/0139). All participants must provide 
written informed consent. The trial will be overseen by 
the INJUSTIS steering group that will include a patient 
representative, and an independent chairperson. The results 
from this study will be submitted for publication in peer-
reviewed journals and disseminated at regional and national 
conferences.
Trial registration number NCT03670576
InTRoduCTIon
Interstitial lung diseases (ILDs) are a group of 
immunoinflammatory and fibrotic diseases of 
the lung parenchyma. In a substantial number 
of patients there is progressive fibrosis of 
the alveoli and interstitium that leads to 
increasing disability and ultimately the death 
of patients with these diseases. Establishing 
the aetiology of these fibrotic lung diseases is 
often a clinical challenge and the relevance of 
aetiology to disease behaviour remains contro-
versial. The best characterised fibrotic ILD is 
idiopathic pulmonary fibrosis (IPF), which 
has a median survival of 3 years, and 5-year 
survival of 25%, which is worse than most 
cancers.1 Other conditions characterised by 
progressive pulmonary fibrosis include asbes-
tosis, chronic hypersensitivity pneumonitis 
(HP), rheumatoid arthritis-associated ILD 
(RA-ILD), where the aetiology is assumed, 
and unclassifiable ILD where the clinical 
phenotype does not precisely reflect IPF.2 The 
progression of these related conditions is also 
remorseless, and their genetic predisposition 
similar to IPF, raising the possibility of shared 
targetable mechanisms across disease pheno-
types regardless of likely aetiology.
Recently two drugs, pirfenidone3 4 and 
nintedanib,5 have been approved for the treat-
ment of IPF. While these drugs are described 
as ‘anti-fibrotic’, they can only be prescribed 
for IPF, rather than all forms of progressive 
fibrotic disease.6 Therefore, patients with 
pulmonary fibrosis where the aetiology has 
been assumed, or the clinical features aren’t 
specific for IPF, cannot receive antifibrotic 
therapy at the current time. However, the 
risk factors and molecular pathways driving 
fibrosis in aetiologically defined or pheno-
typically unusual pulmonary fibrosis may be 
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similar to IPF, thus potentially resulting in a large number 
of patients not having access to life-prolonging therapy. 
Our understanding of IPF has improved significantly 
both in terms of biomarkers7 8 and clinical end points.9 
However, there remains a significant gap in our under-
standing of non-IPF ILD, with currently no approved 
treatments or cure.
RA-ILD, seen in 5%–10% of patients with rheumatoid 
arthritis remains a significant life-limiting complication 
with mortality in excess of 10% compared with patients 
without ILD. Subclinical interstitial lung abnormalities 
(ILAs) are seen in 30%–50% but individual risk of progres-
sion to ILD is unknown.10 Chronic HP diagnosis rests on 
history of antigen exposure and radiological appearance, 
which often has an overlap with other ILDs. Sometimes, 
there is no known antigen exposure, and more recent 
hypotheses suggest a combination of exposure in genet-
ically predisposed individuals.11 12 While acute HP has 
a good prognosis, chronic HP is a progressive disease 
lacking evidence-based treatments with current therapy 
relying on immunosuppression. Despite improvements 
in radiology and the advent of multidisciplinary teams 
(MDTs), unclassifiable ILD remains a significant burden 
of ILD in clinical practice and represents between 10% 
and 38% of all ILDs.13 14 These patients present a diag-
nostic challenge and again no evidence-based treatments 
are available.
Recent studies have highlighted phenotypical and 
molecular similarities across a range of ILDs. For 
example, the minor allele frequency of the MUC5B 
promoter single-nucleotide polymorphism (SNP), widely 
associated with IPF,15 is found with increasing frequency 
in patients with chronic HP.16 Short telomeres have also 
been associated with RA-ILD17 and chronic HP, resulting 
in a prognosis similar to patients with IPF.16 Patients with 
RA-ILD and usual interstitial pneumonia pattern have 
radiological changes that are indistinguishable from IPF 
and the presence of traction change and honeycombing 
is associated with poor outcomes regardless of aetiology.
Together, these features suggest that there may be 
shared mechanisms in the progression of pulmonary 
fibrosis common among patients with lung fibrosis due 
to a number of aetiologies. To explore this hypothesis, 
the Its Not JUST Idiopathic pulmonary fibrosis Study 
(INJUSTIS) will recruit a clinical cohort comprising of 
ILD subgroups, to explore genetic, serum and clinical 
biomarkers that may distinguish progressive fibrosing 
lung disease phenotypes regardless of aetiology. This may 
then eventually enable therapeutics targeting specific 
mechanisms of disease rather than clinical phenotypes of 
disease.
METhodS And AnAlySIS
objectives
INJUSTIS is a prospective multicentre observa-
tional cohort study that will be managed through the 
Nottingham Respiratory Research Unit and funded 
by the National Institute of Health Research (NIHR) 
through the Nottingham Biomedical Research Centre 
and an NIHR professorship (RGJ).
The primary objective is to:
 ► Identify biomarkers that determine progressive 
fibrotic lung disease irrespective of aetiology.
The secondary objectives are to:
 ► Identify biomarkers that predict all-cause mortality.
 ► Identify biomarkers that predict changes in QoL 
scores.
 ► Identify biomarkers that predict the development of 
disease complications (respiratory failure and acute 
exacerbations).
 ► Investigate genetic association and epigenetic modi-
fications which affect fibrotic disease severity and 
progression.
 ► Prospectively evaluate longitudinal disease behaviour 
in patients with non-IPF fibrotic lung diseases with a 
view to developing composite clinical end points for 
subsequent use in intervention studies.
 ► Explore association of environmental exposures with 
disease progression and all-cause mortality.
 ► Investigate whether home handheld spirometry over 
3 months predicts disease progression and survival.
The primary end point will be:
 ► Disease progression defined as relative forced vital 
capacity decline ≥10% or death within 12 months.
Secondary end points are:
 ► All-cause mortality at time of censoring.
 ► Number of acute exacerbations over 2 years.
 ► Change in Quality of Life (QoL) Questionnaire 
Scores from baseline to 12 weeks.
 ► Rate of change in biomarker activity from baseline to 
12 weeks.
 ► Change in diffusing capacity of the lung for carbon 
monoxide (DLco) from baseline to 12 months.
 ► Change in 6 min walk distance from baseline to 12 
months.
 ► Change in transcriptomic profiles from baseline to 12 
weeks.
 ► Change in home handheld spirometry values from 
baseline to 12 weeks.
Selection of participants
Two hundred participants with recently diagnosed 
(within 18 months of study start date) fibrotic lung 
disease (50 each of rheumatoid-ILD, asbestosis, chronic 
HP and unclassifiable ILD) and 50 IPF participants 
as positive controls will be recruited from ILD clinics 
locally and across the UK. Only participants with MDT 
confirmed diagnosis of fibrotic ILD with radiological 
evidence of parenchymal lung fibrosis evidenced by 
reticulation and traction bronchiectasis, with or without 
honeycomb change will be recruited. Those with inflam-
matory radiological changes without evidence of fibrosis 
will not be deemed suitable regardless of clinical pheno-
type.
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Recruitment will be reviewed on an ongoing basis and 
should rates fall below the expected levels, additional 
National Health Service (NHS) sites within the UK will 
be considered for participation. Eligible patients who 
meet the inclusion/exclusion criteria will be invited to 
consent. Most participants will be identified through 
outpatient clinics, but recruitment will not be restricted 
to this route. It will be explained to participants that 
entry into the study is entirely voluntary and that further 
treatment and care will not be affected by a decision to 
not partake. It will be clearly stated that participants are 
free to withdraw from the trial at any time. All partici-
pants will provide written informed consent, which will 
be countersigned by a member of the study team.
Inclusion criteria:
 ► Male or female aged ≥18 years.
 ► Able and willing to give written informed consent.
 ► Recently diagnosed (defined as diagnostic CT scan or 
surgical lung biopsy (if applicable) within 18 months 
of study start date).
 ► An MDT diagnosis of fibrotic ILD defined as the 
presence of traction change and reticulation with or 
without honeycombing within the lung parenchyma 
associated with either:
 – Rheumatoid arthritis (rheumatologist diagnosed 
with anti-cyclic citrullinated peptide antibodies 
and/or rheumatoid factor positive).
 – Asbestosis (appropriate occupational history and 
radiological evidence of asbestos exposure).
 – Chronic HP in accordance with consensus crite-
ria11 (appropriate exposure history, radiological 
features ± avian and fungal precipitins).
 – Unclassifiable fibrotic lung disease (fibrotic lung 
disease otherwise unclassifiable despite extensive 
clinical and radiological examination).
 – IPF in accordance with consensus criteria 
(American Thoracic Society (ATS), European 
Respiratory Society (ERS), Japanese Respiratory 
Society (JRS, Latin American Thoracic Society 
(ALAT) guidelines).18 19
Exclusion criteria:
 ► Participating in an interventional clinic trial.
 ► Asymptomatic ILAs and normal lung function.
 ► Change in clinical phenotype from initial radiolog-
ical diagnosis to screening.
 ► Any connective tissue disease other than rheumatoid 
arthritis.
 ► Acute HP.
 ► Participants who do not possess a smartphone cannot 
partake in the domiciliary spirometry.
Study regimen
Both cases and IPF controls will undertake the same inves-
tigations. Following informed consent, the following test 
results, previously carried out as part of the participant’s 
usual NHS care, will be used for the purposes of the study:
 ► HRCT findings.
 ► Blood results.
 ► Lung function tests.
 ► Bronchoscopy samples if already taken.
All participants will have baseline investigations at 
the first visit having provided informed consent. At the 
first visit, 40 mL of blood will be obtained, full lung 
function tests and a 6 min walk test will be performed. 
Participants will also be asked to complete QoL Ques-
tionnaires (Medical Research Council Dyspnoea Scale,20 
Leicester Cough Questionnaire (need to include refer-
ence here: https:// thorax. bmj. com/ content/ 58/ 4/ 
339), IPF-abridged Profile for Assessment and Referral 
to Care,21 King’s Brief ILD Questionnaire22 and 
EQ-5D-5L).23 If consent is given for optional bronchos-
copy, this will be subsequently performed and bronchoal-
veolar lavage carried out. Participants with a smartphone 
will be given the option of a home handheld spirometer 
and asked to provide daily FVC readings for the first 3 
months of the study period.
Further visits at 3 months, 12 months and 24 months 
will include further 40 mL blood sampling, QoL and full 
lung function analysis. At 12 months and 24 months a 6 
min walk test will be repeated (figure 1).
The majority of initial sample processing will be 
performed at the participant’s local NHS hospital trust 
via the Clinical Research Network. Participation in the 
study will be for 2 years. Other than initial assessment and 
follow-up visits at 3 months, 12 months and 24 months, 
there will be no further assessments. Only participants 
recruited at Nottingham University Hospitals NHS Trust 
will be offered a study bronchoscopy. It is not anticipated 
that any data will be obtained before completion of study 
that would lead to discontinuation of the study. For indi-
vidual participants, discontinuation will be decided on an 
individual basis. The end of study will be defined as the 
last patient to complete the 2 years of follow-up.
Specimen processing and analysis
All human tissue (blood, lavage, biopsy, etc.) samples 
will be processed and stored in accordance with the 
Human Tissue Act (2004). All biological samples will be 
processed within 2 hours of being obtained according to 
local standard operating procedures and stored in 500 
µl aliquots at −80°C until analysis. Sample analysis will 
take place either at the University of Nottingham or in 
the laboratories of third party national, or international, 
academic partners or contract research organisations 
following appropriate tissue transfer agreements.
The primary analysis will include measurement of 
epithelial biomarkers [matrix metalloproteinase-7 
(MMP-7), cancer antigen 125 (CA-125), carbohydrate 
antigen 19-9 (CA19-9), surfactant protein D (SP-D)]) 
and markers of matrix turnover [C-reactive protein 
degraded by MMP-1/8 (CRPM), collagen 3 degraded 
by MMP-9 (C3M) and collagen 6 degraded by MMP-2/9 
(C6M)) as well as genotyping for mucin 5B (MUC5B), 
desmoplakin (DSP) and A-kinase anchoring protein 
13 (AKAP13). Exploratory analysis will include whole 
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Figure 1 Legend – participant flow through the study. BMI, body mass index; ILD, interstitial lung disease. The picture in the 
figure is incorrect and the picture belongs to Figure 2 and vice versa. The legends are in the right place but with the wrong 
pictures. Please swap.
genome sequencing, RNA sequencing, proteomic and 
metabolomic analysis to identify novel biomarkers that 
predict fibrotic disease behaviour. Biopsy material will 
be used to culture cellular components, frozen for 
extraction of protein, RNA and DNA or formalin-fixed 
paraffin embedded.
Any additional samples will be archived for future 
genetic and biomarker studies in the University of 
Nottingham premises at the Nottingham City Hospital. 
The Human Tissues Authority license number is 12 265. 
Where participants do not agree to the future use of the 
samples they will be destroyed in accordance with the 
Human Tissue Act, 2004.
Details of spirometry
A secondary objective of this study is to determine whether 
change in daily home (domiciliary) handheld spirometry 
values over 3 months can predict disease progression and 
overall survival.
Participants wishing to take part in home spirometry 
will be provided with a portable handheld spirometer 
(MIR Spirobank Smart) linked to an electronic health 
journal (patientMpower smartphone application) on 
enrolment. Participants will be trained to undertake daily 
spirometry readings (one forced expiratory manoeuvre/
day; seated) for the first 3 months of the study period. All 
spirometry readings will be blinded to participants and 
automatically uploaded to patientMpower via the smart-
phone application, ensuring full encryption throughout. 
Participants will therefore need to possess, and be confi-
dent in using, a smartphone device and have an email 
address. The spirometry data will then be transferred to 
the University of Nottingham for further analysis. Partic-
ipants will be able to continue to use the spirometer and 
patientMpower application with open display of FVC 
readings after the initial 3-month observation period if 
they wish.
Statistics
The primary end point of disease progression (10% rela-
tive FVC decline or death within 12 months) will be used 
dichotomously across all subgroups collectively analysed 
together, with the exception of IPF controls. Association 
of baseline biomarker levels with dichotomous disease 
progression and overall survival will be analysed using 
binomial family of generalised linear models, while 
Gaussian family or otherwise appropriate models will be 
used to assess associations with continuous secondary 
end points. The Benjamini-Hochberg procedure will 
be applied to account for multiplicity as appropriate. 
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Figure 2 Directed acyclic graph (DAG) illustrates proposed model of causal inference and minimal sufficient adjustment sets 
(confounders; red) for estimating the direct effect of biomarker expression profiles (exposure; green) on disease progression 
(outcome; blue). Image generated using DAGitty.net environment. QoL, quality of life. As above, the legend is correct, but the 
flow diagram needs to be in Figure 1, and the DAG in Figure 2.
Repeated measures mixed models will be used to assess 
associations over time, which includes time points within 
one model and circumvents correction for multiple 
testing. Fixed factors will include baseline demographic 
information. Where putative biomarkers are identified, 
end point data will be used to compare biomarker levels 
by time-to-event through proportional hazard models; 
comparable ability to predict end points will be assessed 
through sensitivity and specificity analyses (receiver oper-
ator characteristic curves).
To identify transcriptomic biomarkers, RNA-seq 
libraries will be prepared and entered into a workflow 
for read count normalisation enabling quantification 
of transcript expression; normalisation ensures length 
and abundance of cDNA reads are corrected according 
to other genes (reads per kilobase per million) and 
further library scaling can occur.24 25 Libraries, aligned 
to an appropriate reference genome, will enable detec-
tion of differential gene expression and SNPs/variants 
according to primary end point and secondary measures 
of disease severity. Transcript-discovery artefacts, tran-
scripts that remain below detectable levels of change 
across compared samples, as well as any with zero mapped 
reads will be excluded. R statistical packages will be used 
for these bioinformatics workflows.
Further statistical analyses will be performed to deter-
mine associations between identified biomarkers and 
exploratory secondary objectives. Statistical approaches 
include, but are not limited to, correlation and analyses 
of variance between biomarker levels and patient-re-
ported QoL outcomes or disease exacerbations; machine 
learning strategies on home spirometry to detect 
decline in lung function, and subsequent comparison 
of sensitivity with traditional spirometry measures at 
predicting end points. Factor analysis approaches will 
be used to reduce dimensions of data sets and assess 
clustering; generalised linear models will be used to test 
associations.
Confounding factors are particularly important in 
studies that hope to offer causal inference of biomarkers 
on clinical outcomes,26 and corrections to adjust for 
these will be applied in the analysis as proposed by the 
directed acyclic graph (figure 2).27 Fixed factors in mixed 
models will include baseline demographic information: 
age, gender, body mass index and smoking status. Expo-
sure history in patients with chronic HP will be collected 
as will time from diagnosis to enrolment across all 
subgroups and adjusted for as a potential confounder. 
Some participants may be on background therapies such 
as immunosuppression and corticosteroids. While these 
therapies are likely to be confounders, it is possible they 
may decrease or increase progression of fibrosis based on 
the PANTHER (Prednisone, Azathioprine, and N-Ace-
tylcysteine: A Study That Evaluates Response in Idio-
pathic Pulmonary Fibrosis) Study.28 Therefore, models 
will include treatment strategy as part of the minimal set 
of adjustment for estimating direct effect on end point. 
The objectives of the study do not extend to assessing 
treatment effect. Further unknown confounders will be 
identified from the spirometry smartphone application 
that will collect various data such as air quality index to 
inform limitations and future study.
Sample size justification
A power calculation has been conducted using prior 
data obtained at 3 months in the PROFILE (Prospective 
Observation of Fibrosis in the Lung Clinical Endpoints) 
study of patients with IPF.8 The study demonstrated that 
90 stable and 90 progressive individuals were sufficient to 
detect a twofold change in MMP7 with >90% power and 
5% type I error rate. MMP7 was selected for power calcu-
lation as the most conservative of the biomarkers iden-
tified in the PROFILE Study, with the lowest threshold 
for biomarker change and least statistical precision, thus 
powering on MMP7 ensures that other biomarkers will be 
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analysed with adequate power. The calculation demon-
strates that a sample of 100 participants with progressive 
fibrosis and 100 with stable fibrosis will be large enough 
to detect dynamic differences in biomarkers over 3 
months with 80% power and a type I error rate of 5% 
(α=0.05). Therefore 200 participants with ILD will be 
recruited assuming 50% disease progression. Fifty posi-
tive IPF controls will be recruited to take part in the study 
to benchmark progressive fibrotic lung disease but will 
not be included in the final analysis.
The study is also appropriately powered for genetic 
risk scores. An individual SNP with 25% minor allele 
frequency would have >70% power to detect an OR of 
1.8 for stable versus progressive disease. The power for a 
risk score comprising multiple variants is expected to be 
greater. This assumes an additive genetic model, p<0.05, 
in 100 stable versus 100 progressive patients whereby with 
each additional marker added to the model the power 
is actually increased rather than reduced. The markers 
used will all be defined a priori based on data obtained 
from the PROFILE Study7 8 but are likely to include 
MUC5B, DSP, AKAP13, SP-D, CA-125, CA19-9, MMP-7, 
CRPM and C6M.
Following the recruitment of 100 participants who 
complete 1 year in the study, an interim sample size re-es-
timation by an independent data monitoring committee 
will be conducted to determine the progression status 
between blinded subgroups. If the blinded progression 
status is approximately 50%, recruitment will continue 
as described. If however, any subgroups show a relatively 
stable phenotype they will be excluded from subsequent 
recruitment, after being unblinded to the data moni-
toring committee. To attain an adequately powered 
sample size with 50% progressive fibrosis, further 
recruitment will be enriched with participants from the 
progressive phenotypical subgroups relative to rate of 
progression in interim analysis. Those recruited from 
subsequently excluded subgroups will be removed from 
the primary analysis, as they will be sources of inconsis-
tency. However, if all subgroups progress at a substantially 
lower rate than expected and conditional power calcula-
tions at interim analysis suggest futility then all subgroups 
will be included in an analysis that demonstrates the 
null hypothesis (fibrotic lung disease progress at a rate 
specific to aetiology) could not be rejected. The study is 
not statistically powered to detect differences between 
ILD subgroups, although exploratory analyses will be 
carried out to inform future studies and support replica-
tion studies.
Patient and public involvement
The Action for Pulmonary Fibrosis (APF)29 charity have 
been consulted during the design of the study and will 
sit on the steering committee as patient representatives, 
which will inform study conduct and recruitment. All 
patient information material has been reviewed by patient 
representatives. Study findings will be communicated to 
participants, and the APF will also support the dissemi-
nation of the study’s finding to patients with pulmonary 
fibrosis and their families.
EThICS And dISSEMInATIon
Monitoring
Monitoring of study data will include confirmation of 
informed consent; source data verification; data storage 
and data transfer procedures; local quality control checks 
and procedures, backup and disaster recovery of any local 
databases and validation of data manipulation. Entries 
on case report forms (CRFs) will be verified by inspection 
against the source data. A sample of CRFs (10% or as per 
the study risk assessment) will be checked on a regular 
basis for verification of all entries made. In addition, the 
subsequent capture of the data on the study database will 
be checked. Where corrections are required, these will 
carry a full audit trail and justification.
The study coordinator, or where required, a nomi-
nated designee of the sponsor, shall carry out moni-
toring of study data as an ongoing activity Trial data and 
evidence of monitoring and systems audit will be made 
available for inspection by the research ethics committee 
as required.
Safety reporting
No significant safety concerns are anticipated in relation 
to any measurements carried out as part of this trial. For 
patients undertaking bronchoscopy, the possible risks are 
the same as described in the hospital information sheet 
given prior to the procedure. All adverse events will be 
recorded and closely monitored until resolution, stabili-
sation or until it has been that the study intervention is 
not the cause. The chief investigator shall be informed 
immediately of any serious adverse events and shall deter-
mine seriousness and causality in conjunction with any 
treating medical practitioners.
Trial monitoring and oversight
The trial will be overseen by the INJUSTIS steering group 
consisting of the chief investigator, centre manager, 
research officer, research fellow, statistician, patient 
representatives (APF) and an independent chairperson. 
This committee will meet every 4 months.
Interim analysis will be undertaken by an independent 
data monitoring committee that will comprise two clini-
cians with expertise in clinical trials in ILD and a statisti-
cian not directly involved in this study.
dissemination
All data will be anonymised and grouped for presenta-
tion and publication. The results from this study will be 
publicised at regional and national conferences as well as 
being submitted for publication in open access peer-re-
viewed journals in accordance with UK Research Council 
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policies. No participants will be identified in any publica-
tions that arise from this research.
ConCluSIon
The INJUSTIS is a prospective longitudinal study of 
non-idiopathic fibrotic ILD, that will identify biomarkers 
of progression of fibrotic lung disease regardless of aeti-
ology should such biomarkers exist. However, this study is 
not powered to detect differences between fibrotic lung 
diseases of specific aetiologies, although it may provide 
insights into specific fibrotic lung diseases for further 
investigation.
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